CY1108773T1 - 7-υδροξυεπιανδροστερονη που εχει νευροπροστατευτικη δραση - Google Patents

7-υδροξυεπιανδροστερονη που εχει νευροπροστατευτικη δραση

Info

Publication number
CY1108773T1
CY1108773T1 CY20081101165T CY081101165T CY1108773T1 CY 1108773 T1 CY1108773 T1 CY 1108773T1 CY 20081101165 T CY20081101165 T CY 20081101165T CY 081101165 T CY081101165 T CY 081101165T CY 1108773 T1 CY1108773 T1 CY 1108773T1
Authority
CY
Cyprus
Prior art keywords
hydroxyapiandrosterone
neuroprotective action
neuroprotective
action
hydroxyepiandrosterone
Prior art date
Application number
CY20081101165T
Other languages
English (en)
Inventor
Ashley Ker Pringle
Lars Eric Sundstrom
Ernst Wülfert
Original Assignee
Hunter-Fleming Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter-Fleming Limited filed Critical Hunter-Fleming Limited
Publication of CY1108773T1 publication Critical patent/CY1108773T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Η 7-Υδροξυεπιανδροστερόνη μπορεί να χρησιμοποιηθεί για προστασία έναντι της οξείας ή της χρόνιας νευρωνικής βλάβης.
CY20081101165T 2000-06-29 2008-10-20 7-υδροξυεπιανδροστερονη που εχει νευροπροστατευτικη δραση CY1108773T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0016022A GB2363983A (en) 2000-06-29 2000-06-29 Protection against neuronal damage using 7-hydroxyepiandrosterone
EP01945494A EP1294382B1 (en) 2000-06-29 2001-06-29 7-hydroxyepiandrosterone having neuroprotective activity

Publications (1)

Publication Number Publication Date
CY1108773T1 true CY1108773T1 (el) 2014-04-09

Family

ID=9894707

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101165T CY1108773T1 (el) 2000-06-29 2008-10-20 7-υδροξυεπιανδροστερονη που εχει νευροπροστατευτικη δραση

Country Status (24)

Country Link
US (2) US7718639B2 (el)
EP (1) EP1294382B1 (el)
JP (1) JP4942905B2 (el)
KR (1) KR100786284B1 (el)
CN (1) CN100459980C (el)
AT (1) ATE401897T1 (el)
AU (2) AU6770901A (el)
CA (1) CA2414584C (el)
CY (1) CY1108773T1 (el)
CZ (1) CZ299676B6 (el)
DE (1) DE60134979D1 (el)
DK (1) DK1294382T3 (el)
ES (1) ES2310182T3 (el)
GB (1) GB2363983A (el)
HK (1) HK1052300B (el)
HU (1) HU227152B1 (el)
IL (2) IL153541A0 (el)
NO (1) NO327959B1 (el)
PL (1) PL200699B1 (el)
PT (1) PT1294382E (el)
RU (1) RU2307654C2 (el)
SI (1) SI1294382T1 (el)
WO (1) WO2002000225A1 (el)
ZA (1) ZA200300085B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
US8580983B2 (en) * 2006-11-21 2013-11-12 Umecrine Ab Steroids having increased water solubility and resistance against metabolism, and methods for their production
PL2097079T3 (pl) 2006-11-30 2012-11-30 Hunter Fleming Ltd Modulowanie szlaków metabolicznych prostaglandyna/cyklooksygenaza
GB0623971D0 (en) * 2006-11-30 2007-01-10 Hunter Fleming Ltd Modulation of prostaglandin/cyclooxygenase metabolic pathways

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU243975A (en) 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5707983A (en) 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
JP2858046B2 (ja) 1993-03-09 1999-02-17 ユニバーシティ オブ ユタ リサーチ ファウンデーション 組織損傷を有する個人の組織生活能力の消失の予防乃至は軽減のための製薬組成
US5846963A (en) 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5877169A (en) 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
US5976850A (en) 1994-10-19 1999-11-02 University Of Edinburgh Hippocampus-associated proteins; DNA sequences coding therefor and uses thereof
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
PT837874E (pt) 1995-06-06 2005-03-31 Euro Celtique Sa Esteroides neuroactivos da serie androstano e pregnano
EP0840612A1 (en) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
GB2317826B (en) * 1995-08-29 1999-12-15 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
CA2250874A1 (en) 1996-04-09 1997-10-16 Btg International Limited Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
DK0929574T3 (da) 1996-08-27 2005-10-31 Praecis Pharm Inc Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
FR2760362B1 (fr) 1997-03-10 2000-08-11 Vitasterol Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
GB9708716D0 (en) * 1997-04-29 1997-06-18 Imperial College Chronic heart failure
US6544972B1 (en) * 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
AU1387399A (en) 1997-11-10 1999-05-31 Vyrex Corporation Probucol esters and uses thereof
US6172088B1 (en) * 1997-11-24 2001-01-09 University Of Florida Research Foundation, Inc. Testosterone compounds and use for the protection of neurons
GB9726569D0 (en) 1997-12-16 1998-02-11 Univ Southampton Neuroprotective agents
WO1999052532A1 (en) * 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
FR2786102B1 (fr) * 1998-11-20 2001-02-16 Monique Vincens Utilisation de sulfate de dehydroepiandrosterone pour augmenter le nombre de recepteurs nmda chez un mammifere
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
JP2003513102A (ja) 1999-11-02 2003-04-08 シエーリング アクチエンゲゼルシャフト 選択的な作用を有するエストロゲンとしての１８−ノル−ステロイド
GB0003524D0 (en) 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders

Also Published As

Publication number Publication date
KR20030034113A (ko) 2003-05-01
ES2310182T3 (es) 2009-01-01
GB0016022D0 (en) 2000-08-23
CN100459980C (zh) 2009-02-11
SI1294382T1 (sl) 2009-02-28
US20030166626A1 (en) 2003-09-04
US20100173883A1 (en) 2010-07-08
CA2414584A1 (en) 2002-01-03
US7718639B2 (en) 2010-05-18
DE60134979D1 (de) 2008-09-04
NO327959B1 (no) 2009-10-26
RU2003102437A (ru) 2005-01-27
IL153541A0 (en) 2003-07-06
HUP0301134A3 (en) 2006-06-28
CN1440290A (zh) 2003-09-03
HU227152B1 (en) 2010-08-30
PT1294382E (pt) 2008-10-21
HK1052300A1 (en) 2003-09-11
WO2002000225A1 (en) 2002-01-03
JP2004501196A (ja) 2004-01-15
AU6770901A (en) 2002-01-08
ATE401897T1 (de) 2008-08-15
RU2307654C2 (ru) 2007-10-10
PL200699B1 (pl) 2009-01-30
GB2363983A (en) 2002-01-16
ZA200300085B (en) 2004-04-21
CZ299676B6 (cs) 2008-10-15
IL153541A (en) 2008-03-20
CZ200377A3 (cs) 2003-06-18
DK1294382T3 (da) 2008-11-24
EP1294382B1 (en) 2008-07-23
NO20026243D0 (no) 2002-12-27
NO20026243L (no) 2003-02-27
HK1052300B (zh) 2009-01-30
KR100786284B1 (ko) 2007-12-18
CA2414584C (en) 2009-10-27
AU2001267709B2 (en) 2005-07-28
EP1294382A1 (en) 2003-03-26
JP4942905B2 (ja) 2012-05-30
PL359108A1 (en) 2004-08-23
HUP0301134A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
CY1108773T1 (el) 7-υδροξυεπιανδροστερονη που εχει νευροπροστατευτικη δραση
DE60125931D1 (de) Schutzvorrichtung
NO20025045L (no) Strukturelt modifiserte polymerflokkuleringsmidler
NO20024562L (no) Seismiske kildegrupper
AR028423A1 (es) Inhibidores de la replicacion del hiv
BR0107247B1 (pt) braçadeira para mangueira.
ATE279413T1 (de) Pyrazolobenzodiazepine mit cdk2 hemmender wirkung
ITMI20010819A0 (it) Struttura decorativa e di protezione per lampade del tipo ad occhio di granchio senza portalampade
DE50113389D1 (de) Lichtquelle
DE60123702D1 (de) Bogenverarbeitungsvorrichtung
DE60110352D1 (de) Mehrstufige verarbeitungs-vorrichtung
ITFI20030216A1 (it) Condotto di distribuzione del carburante in un
PT9704T (pt) Banda com decoracoes que pode enrolar-se
DE60138857D1 (de) Multiport-Cachespeicher
DE50101736D1 (de) Karde
ATE281673T1 (de) Multiportkarte
DE50101588D1 (de) Klemmstück
ATA372000A (de) Texturierdüse
DE60104315D1 (de) Fingerschutzanordnung
FI20002186A (fi) Valaisinjärjestely
IT249532Y1 (it) Dispositivo luminoso.
DE60103065D1 (de) Druckentlastungsvorrichtung
IT1320063B1 (it) Dispositivo di illuminazione.
FI20000305A (fi) Pistotulpalla varustettu valaisinjohto Tiivisterakenne rautatietavaravaunun siirrettävää katetta varten
DE50114582D1 (de) Texturierdüse